IL258090B2 - Immunogenic detection of antigen from a pathogen and adjustment of effective clinical treatment - Google Patents

Immunogenic detection of antigen from a pathogen and adjustment of effective clinical treatment

Info

Publication number
IL258090B2
IL258090B2 IL258090A IL25809018A IL258090B2 IL 258090 B2 IL258090 B2 IL 258090B2 IL 258090 A IL258090 A IL 258090A IL 25809018 A IL25809018 A IL 25809018A IL 258090 B2 IL258090 B2 IL 258090B2
Authority
IL
Israel
Prior art keywords
cells
antigen
cancer
antigens
cell
Prior art date
Application number
IL258090A
Other languages
English (en)
Hebrew (he)
Other versions
IL258090B (en
IL258090A (en
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of IL258090A publication Critical patent/IL258090A/en
Publication of IL258090B publication Critical patent/IL258090B/en
Publication of IL258090B2 publication Critical patent/IL258090B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
IL258090A 2015-09-18 2016-09-19 Immunogenic detection of antigen from a pathogen and adjustment of effective clinical treatment IL258090B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562220884P 2015-09-18 2015-09-18
PCT/US2016/052487 WO2017049291A1 (en) 2015-09-18 2016-09-19 Immunogenic antigen identification from a pathogen and correlation to clinical efficacy

Publications (3)

Publication Number Publication Date
IL258090A IL258090A (en) 2018-05-31
IL258090B IL258090B (en) 2022-12-01
IL258090B2 true IL258090B2 (en) 2023-04-01

Family

ID=58289728

Family Applications (2)

Application Number Title Priority Date Filing Date
IL258090A IL258090B2 (en) 2015-09-18 2016-09-19 Immunogenic detection of antigen from a pathogen and adjustment of effective clinical treatment
IL298359A IL298359B2 (en) 2015-09-18 2016-09-19 Immunogenic antigen identification from a pathogen and correlation to clinical efficacy

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL298359A IL298359B2 (en) 2015-09-18 2016-09-19 Immunogenic antigen identification from a pathogen and correlation to clinical efficacy

Country Status (10)

Country Link
US (3) US11167024B2 (enExample)
EP (2) EP3350600A4 (enExample)
JP (3) JP6999941B2 (enExample)
CN (3) CN108449994B (enExample)
AU (2) AU2016324479B2 (enExample)
CA (1) CA2998649A1 (enExample)
HK (1) HK1258649A1 (enExample)
IL (2) IL258090B2 (enExample)
SG (1) SG10202112047TA (enExample)
WO (1) WO2017049291A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
BR112021019120A2 (pt) * 2019-03-25 2021-11-30 Baylor College Medicine Células t específicas para antígenos de múltiplos vírus respiratórios e métodos de produção e uso das mesmas terapeuticamente
EP3976068A4 (en) * 2019-05-31 2023-08-09 Children's National Medical Center CYTOKIN COCKTAILS FOR SELECTIVE EXPANSION OF T-CELL SUBSETS
EP4013897A4 (en) 2019-08-16 2024-07-24 Baylor College of Medicine THIRD PARTY VIRUSPECIFIC T-CELL COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF IN ANTIVIRAL PROPHYLAXIS
WO2021119293A2 (en) * 2019-12-10 2021-06-17 Children's National Medical Center T-cell epitopes of human parainfluenza virus 3 for adoptive t-cell immunotherapy
WO2021133667A1 (en) * 2019-12-23 2021-07-01 Baylor College Of Medicine T cell performance assay as a prognostic factor for clinical outcome
WO2022192402A1 (en) * 2021-03-10 2022-09-15 Avail Bio, Inc. Methods, compositions, and systems for b-cell isolation sequencing
WO2026070936A1 (ja) * 2024-09-26 2026-04-02 国立大学法人東京科学大学 抗原特異的ｔ細胞の製造方法、および製造用キット

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050569A1 (en) * 1999-02-24 2000-08-31 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
US20020051784A1 (en) * 1994-03-08 2002-05-02 Dana Farber Cancer Institute Methods for modulating T cell unresponsiveness
US7785806B2 (en) * 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
US9115402B2 (en) * 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641628A (en) 1989-11-13 1997-06-24 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal DNA
WO1994002156A1 (en) 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
US6821778B1 (en) 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
WO1995027722A1 (en) 1994-04-06 1995-10-19 Immunex Corporation Interleukin-15
JP3288708B2 (ja) 1994-05-16 2002-06-04 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗原特異的細胞障害性ｔ細胞の養子移入の手段による免疫調節の方法
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
ATE211172T1 (de) 1995-06-06 2002-01-15 Organon Teknika Bv Epstein-barr viruspeptide, und antikörper gegen diese peptide
FR2745185B1 (fr) 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
US6699477B2 (en) 1996-05-24 2004-03-02 The Council Of The Queensland Institute Of Medical Research EBV CTL epitopes
US5962318A (en) 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
JP2001509677A (ja) 1997-01-31 2001-07-24 エピミューン，インコーポレイティド Ｃｔｌを活性化するためのペプチドおよびペプチド担持抗原提示細胞
US6528307B1 (en) 1997-04-25 2003-03-04 The Wistar Institute Of Anatomy And Biology Cytolytic T-cell clones against colorectal carcinoma
US7951383B2 (en) * 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
US20020155108A1 (en) 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
US6828147B1 (en) 1999-02-24 2004-12-07 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
US7005131B1 (en) 1999-08-13 2006-02-28 The Rockefeller University Protective antigen of Epstein Barr Virus
US20150037297A1 (en) 1999-08-30 2015-02-05 David S Terman Sickled Erythrocytes and Progenitors Target Cytotoxics to Tumors
ES2383418T3 (es) 1999-11-24 2012-06-21 Red Cliff Holding Agente celular antiangiogénico para la terapia del cáncer.
DE10009341A1 (de) 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
EP1297017B1 (en) 2000-06-19 2012-06-13 Beth Israel Deaconess Medical Center Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
EP1326961B1 (en) 2000-09-15 2007-08-22 Ortho-McNeil Pharmaceutical, Inc. Compositions and methods for inducing specific cytolytic t cell responses
EP1229043A1 (en) 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
GB0107628D0 (en) 2001-03-27 2001-05-16 Avidex Ltd Substances
US20040022761A1 (en) 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
ATE438710T1 (de) 2001-05-15 2009-08-15 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
ES2255574T3 (es) 2001-09-28 2006-07-01 Heinrich-Gunter Schumacher Cuchilla de segado con una guia de cuchilla co0nstituida por guias parciales.
US20030153073A1 (en) 2001-11-07 2003-08-14 Paul Rogers Expansion of T cells in vitro and expanded T cell populations
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
DE60234115D1 (de) 2001-11-29 2009-12-03 Dandrit Biotech As Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
US20040096457A1 (en) 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
WO2004041849A1 (en) 2002-11-07 2004-05-21 The Council Of The Queensland Institute Of Medical Research Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
AU2002953238A0 (en) 2002-12-09 2003-01-02 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland In vitro immunization
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
CN101120083B (zh) 2003-10-08 2013-03-27 威尔森沃尔夫制造公司 利用透气性材料进行细胞培养的方法及装置
US20050221481A1 (en) 2004-03-30 2005-10-06 Istituto Superiore Di Sanita' Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
US20060045883A1 (en) 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
JP4731867B2 (ja) 2004-10-01 2011-07-27 国立大学法人三重大学 Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法
US20060204509A1 (en) 2005-03-14 2006-09-14 Harty John T Accelerated CD8+ T-cell memory after dendritic cell vaccination
EP1712615A1 (en) 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
DE602006010934D1 (de) 2005-04-20 2010-01-21 Hoffmann La Roche Verfahren zur Identifizierung von Epitopen in Zusammenhang mit Immunogenität bei Biopharmazeutika
WO2006124412A2 (en) 2005-05-11 2006-11-23 The Trustees Of The University Of Pennsylvania Methods for the rapid expansion of antigen specific t-cells
US20070003531A1 (en) 2005-06-30 2007-01-04 University Of Connecticut Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes
US20100035282A1 (en) 2005-08-03 2010-02-11 Maria Chiara Bonini Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes
JP4824389B2 (ja) 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
US20070196389A1 (en) 2005-11-18 2007-08-23 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
GB0604170D0 (en) * 2006-03-02 2006-04-12 Antitope Ltd T cell assays
PT1989544E (pt) 2006-03-02 2011-09-26 Antitope Ltd Ensaios com células t
WO2007121276A2 (en) 2006-04-12 2007-10-25 Biocept, Inc. Enrichment of circulating fetal dna
WO2008025992A2 (en) 2006-09-01 2008-03-06 Cambridge Enterprise Limited Methods of expanding non-effector cd8 t-cell populations
CA2670107A1 (en) 2006-11-22 2008-06-05 The Board Of Trustees Of The University Of Arkansas Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer
JP2010512149A (ja) 2006-12-07 2010-04-22 ウィルソン ウォルフ マニュファクチャリング コーポレイション 細胞培養に効果的な装置および方法
WO2008073312A2 (en) 2006-12-08 2008-06-19 Attenuon, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
DE102006060824B4 (de) * 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
WO2008148170A1 (en) * 2007-06-08 2008-12-11 The University Of Queensland Human metapneumovirus immunogenic peptides, compositions, and methods of use
WO2009042215A2 (en) 2007-09-27 2009-04-02 The Board Of Trustees Of The University Of Arkansas Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
US20100254958A1 (en) 2007-10-24 2010-10-07 Anne Letsch Antigen-Specific T-Cell Preparations from Bone Marrow
EP3085707B1 (en) 2007-11-01 2019-02-27 Mayo Foundation for Medical Education and Research Hla-dr binding peptides and their uses
EP2065462A1 (en) 2007-11-27 2009-06-03 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens
EP2321407A4 (en) 2008-09-11 2012-07-18 Univ Florida SYSTEM AND METHOD FOR THE PRODUCTION OF T-CELLS
CN101824400B (zh) 2009-03-05 2012-08-08 中国科学院微生物研究所 一种放大增殖抗原特异性t细胞的方法
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
JP5833443B2 (ja) 2009-08-29 2015-12-16 株式会社バイオメッドコア 抗原特異的ｔ細胞誘導能測定法
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
WO2011072088A2 (en) 2009-12-08 2011-06-16 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US9114100B2 (en) 2010-05-17 2015-08-25 Duke University Methods of treatment using ex vivo expansion of cord blood T cells
EP2600890A1 (en) 2010-08-04 2013-06-12 Instituto Europeo di Oncologia S.r.l. Method of antigen loading for immunotherapy
US8741642B2 (en) 2010-10-22 2014-06-03 Virginia Commonwealth University Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects
EP2453243A1 (en) 2010-11-11 2012-05-16 Cosmo S.p.A. Method for the diagnosis and/or follow up of the evolution of a tumor
US20130045491A1 (en) 2011-07-19 2013-02-21 Derya Unutmaz Methods for activating t cells
SG11201400513PA (en) 2011-09-08 2014-06-27 Yeda Res & Dev Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
BR112014014591A8 (pt) 2011-12-12 2017-07-04 Baylor College Medicine processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
US20130217122A1 (en) 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
EP2847322B1 (en) 2012-05-08 2019-06-26 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of cd4+ t cell populations
AU2014351871B2 (en) 2013-11-22 2020-02-13 Cellectis Method for generating batches of allogeneic T-cells with averaged potency
EP3097416A2 (en) * 2014-01-21 2016-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for testing t cell priming efficacy in a subject
WO2016073595A1 (en) 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
EP3215165B1 (en) 2014-11-05 2020-12-23 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy
CA2980039A1 (en) 2015-03-20 2016-09-29 Children's National Medical Center Generating virus or other antigen-specific t cells from a naive t cell population
HK1254397A1 (zh) 2015-06-26 2019-07-19 纪念斯隆-凯特林癌症中心 通过t细胞疗法治疗cmv视网膜炎的方法
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
CN109475578A (zh) 2016-05-25 2019-03-15 昆士兰医学研究所理事会 使用同种异体t细胞治疗自身免疫疾病的方法
JP7002769B2 (ja) 2016-09-16 2022-02-04 ベイラー カレッジ オブ メディスン ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム
TW201814042A (zh) 2016-09-26 2018-04-16 新加坡商泰莎治療私人有限公司 T細胞擴展方法
EP3641807A4 (en) 2017-06-22 2021-04-21 The Westmead Institute For Medical Research ADOPTIVE T-CELL THERAPY 2
CA3074734A1 (en) 2017-09-06 2019-03-14 Nant Holdings Ip, Llc Hla tissue matching and methods therefor
GB201808651D0 (en) 2018-05-25 2018-07-11 Rolls Royce Plc Rotor blade arrangement
BR112021019120A2 (pt) 2019-03-25 2021-11-30 Baylor College Medicine Células t específicas para antígenos de múltiplos vírus respiratórios e métodos de produção e uso das mesmas terapeuticamente
TWI867324B (zh) 2019-05-08 2024-12-21 美商百歐恩泰美國公司 T細胞製備組合物及方法
CA3143627A1 (en) 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines
US20220257654A1 (en) 2019-07-23 2022-08-18 Baylor College Of Medicine Antigen-specific t cell banks and methods of making and using the same therapeutically
WO2021021937A1 (en) 2019-07-29 2021-02-04 Baylor College Of Medicine Antigen-specific t cell banks and methods of making and using the same therapeutically
EP4013897A4 (en) 2019-08-16 2024-07-24 Baylor College of Medicine THIRD PARTY VIRUSPECIFIC T-CELL COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF IN ANTIVIRAL PROPHYLAXIS
WO2021133667A1 (en) 2019-12-23 2021-07-01 Baylor College Of Medicine T cell performance assay as a prognostic factor for clinical outcome
WO2021189084A1 (en) 2020-03-20 2021-09-23 Baylor College Of Medicine Sars-cov2-specific t cell compositions and their use in treating and preventing coronavirus and other respiratory virus infections
EP3974029A1 (en) 2020-09-25 2022-03-30 Universidad Autónoma de Madrid Memory t cells as adoptive cell therapy for viral infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020051784A1 (en) * 1994-03-08 2002-05-02 Dana Farber Cancer Institute Methods for modulating T cell unresponsiveness
WO2000050569A1 (en) * 1999-02-24 2000-08-31 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
US7785806B2 (en) * 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
US9115402B2 (en) * 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEEN, A. N. N., ET AL., DIFFERENTIAL IMMUNOGENICITY OF EPSTEIN-BARR VIRUS LATENT-CYCLE PROTEINS FOR HUMAN CD4+ T-HELPER 1 RESPONSES, 15 September 2001 (2001-09-15) *

Also Published As

Publication number Publication date
JP2022002511A (ja) 2022-01-11
CN113943703A (zh) 2022-01-18
IL258090B (en) 2022-12-01
US11931408B2 (en) 2024-03-19
AU2022268286B2 (en) 2026-02-26
SG10202112047TA (en) 2021-12-30
IL258090A (en) 2018-05-31
JP2024045272A (ja) 2024-04-02
JP6999941B2 (ja) 2022-02-10
IL298359B1 (en) 2025-08-01
CN108449994A (zh) 2018-08-24
IL298359A (en) 2023-01-01
EP4290238A3 (en) 2024-09-11
US20250009870A1 (en) 2025-01-09
CA2998649A1 (en) 2017-03-23
US20180250384A1 (en) 2018-09-06
AU2016324479B2 (en) 2022-12-01
US20220001005A1 (en) 2022-01-06
EP3350600A1 (en) 2018-07-25
AU2016324479A1 (en) 2018-04-12
EP4290238A2 (en) 2023-12-13
CN108449994B (zh) 2021-10-01
EP3350600A4 (en) 2019-04-17
CN113791213A (zh) 2021-12-14
AU2022268286A1 (en) 2022-12-15
IL298359B2 (en) 2025-12-01
HK1258649A1 (zh) 2019-11-15
JP7429051B2 (ja) 2024-02-07
US11167024B2 (en) 2021-11-09
JP2018529339A (ja) 2018-10-11
WO2017049291A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
AU2022268286B2 (en) Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
Mendez-Gomez et al. RNA aggregates harness the danger response for potent cancer immunotherapy
Saglio et al. The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care
Diamond et al. A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection
CN114502180A (zh) 抗原特异性t细胞库及其制备和治疗使用方法
JP2015522263A (ja) 膵臓癌患者用ｄｎａワクチン
IL303106A (en) Antigen specific t cells and methods of making and using same
Vasileiou et al. Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients
IL286629B2 (en) Multi-respiratory virus antigen-specific t cells and methods of making and using the same therapeutically
US20220257654A1 (en) Antigen-specific t cell banks and methods of making and using the same therapeutically
US20160341718A1 (en) Methods for testing t cell priming efficacy in a subject
JP2025508695A (ja) がん治療における免疫チェックポイント阻害剤対化学療法の有効性のための予測バイオマーカーとしての腫瘍変異負荷の使用
Song et al. Canine distemper virus increased the differentiation of CD4+ CD8+ T cells and mRNA expression of inflammatory cytokines in peripheral blood lymphocyte from canine
HK40065472A (en) Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
US12565682B2 (en) Methods of treating cancer
HK40065656A (en) Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
HK40104475A (en) Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
CN112423786B (zh) 用于病毒感染的细胞佐剂
Weinberger et al. The Impact of Immunosenescence and Senescence of Immune Cells on Responses to Infection and Vaccination
HK40072178A (en) Antigen-specific t cell banks and methods of making and using the same therapeutically
Lopez-Vergès et al. INAUGURAL ARTICLE by a Recently Elected Academy Member: Expansion of a unique CD57+ NKG2Chi natural killer cell subset during acute human cytomegalovirus infection